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Summary
X-linked chondrodysplasia punctata (CDPX) is a con-
genital disorder characterized by abnormalities in car-
tilage and bone development. Mutations leading to
amino acid substitutions were identified recently in
CDPX patients, in the coding region of the arylsulfatase
E (ARSE) gene, a novel member of the sulfatase gene
family. Transfection of the ARSE full-length cDNA, in
Cos7 cells, allowed us to establish that its protein prod-
uct is a 60-kD precursor, which is subject to N-glyco-
sylation, to give a mature 68-kD form that, unique
among sulfatases, is localized to the Golgi apparatus.
Five missense mutations found in CDPX patients were
introduced into wild-type ARSE cDNA by site-directed
mutagenesis. These mutants were transfected into Cos7
cells, and the arylsulfatase activity and biochemical
properties were determined, to study the effect of these
substitutions on the ARSE protein. One of the mutants
behaves as the wild-type protein. All four of the other
mutations resulted in a complete lack of arylsulfatase
activity, although the substitutions do not appear to af-
fect the stability and subcellular localization of the pro-
tein. The loss of activity due to these mutations confirms
their involvement in the clinical phenotype and points
to the importance of these residues in the correct folding
of a catalytically active ARSE enzyme.
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Introduction
X-linked recessive chondrodysplasia punctata (CDPX;
MIM 302950) is a congenital defect of bone and car-
tilage development, characterized by abnormal calcium
deposits in regions of enchondral bone formation, severe
underdevelopment of nasal cartilage, distal phalangeal
hypoplasia, and short stature (Curry et al. 1984). Inter-
estingly, CDPX displays phenotypic similarities to two
disorders that are due to defects in vitamin K metabolism
and function: Warfarin embryopathy (Hall et al. 1980)
and vitamin K epoxide reductase deficiency (Pauli et al.
1987).
The CDPX critical region was mapped to the distal
part of the short arm of the X chromosome, in Xp22.3
(Wang et al. 1995). In this region, we have identified a
cluster of genes, those for arylsulfatase D (ARSD), aryl-
sulfatase E (ARSE), and arylsulfatase F (ARSF) (Franco
et al. 1995; Puca et al. 1997), that represent novel mem-
bers of the sulfatase gene family. Mutation analysis of
CDPX patients implicated ARSE as the gene responsible
for the disease, and six mutations leading to amino acid
substitutions were identified (Franco et al. 1995; Parenti
et al., 1997).
Sulfatases are a group of enzymes that hydrolyze a
sulfate ester bond in a variety of different compounds.
In addition, a subset of these proteins, the arylsulfatases,
are able to hydrolyze a sulfate group from artificial sub-
strates containing a phenolic ring, such as 4-methylum-
belliferyl (4MU) sulfate. Eleven human sulfatases have
been identified and characterized thus far, and the im-
portance of these enzymes is emphasized by the existence
of inherited disorders that are due to specific sulfatase
deficiencies (Ballabio and Shapiro 1995; Kolodny and
Fluharty 1995; Neufeld and Muenzer 1995; Parenti et
al. 1997). Moreover, a defect in a co- or posttranslational
modification common to all known sulfatases is the basis
of multiple sulfatase deficiency (MSD), an autosomal
recessive disease in which all sulfatase activities are de-
ficient (Kolodny and Fluharty 1995; Schmidt et al.
1995).
The genes for most sulfatases have been cloned by use
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of functional approaches. The recently identified Xp22.3
sulfatases (ARSD, ARSE, and ARSF) were the only sul-
fatases isolated by a positional cloning effort that gave
no indication of their substrate specificity and biochem-
ical properties. Protein-sequence comparison revealed a
high degree of homology with the arylsulfatases and par-
ticularly with steroid sulfatase (STS), the gene for which
is located in the same chromosomal band, Xp22.3 (Bal-
labio et al. 1987; Yen et al. 1987). Genomic studies of
human and primate X and Y chromosomes have indi-
cated that the sulfatase genes present in Xp22.3 evolved
from a common ancestor, thus representing a subfamily
of arylsulfatases (Meroni et al. 1996). Biochemical stud-
ies, after transfection of ARSE cDNA in Cos7 cells, con-
firmed that the ARSE gene product is a heat-labile ar-
ylsulfatase enzyme that hydrolyzes 4MU sulfate at
neutral pH (Franco et al. 1995). Although the natural
substrate is still unknown, this arylsulfatase activity is
competitively inhibited by Warfarin, suggesting the pos-
sible involvement of this enzyme in vitamin K metabo-
lism (Franco et al. 1995; G. Parenti, unpublished data).
In this article, we report the initial functional charac-
terization of ARSE protein and the analysis of the effects
of the mutations found in CDPX patients on the activity,
stability, and subcellular distribution of this enzyme.
Material and Methods
Site-Directed Mutagenesis and Plasmids
Site-directed mutagenesis of the ARSE expression
plasmid (pcDL-ARSE) (Franco et al. 1995) was per-
formed by use of the commercially available Trans-
former II kit (Clontech), in accordance with the man-
ufacturer’s instructions. To introduce mutations R12S,
G137V, R111P, and G245R into wild-type ARSE cDNA,
the following oligonucleotides were used: 5′-GTT TGT
GTT TCA GCA GCT GGC TGC (nt 89–112 of ARSE
cDNA); 5′-CTG AAA GAG AAA GTC TAT GCC ACTG
(nt 462–486 of ARSE cDNA); 5′-GCA TTG GTT ACC
CTG TTC TTC AGT GG (nt 386–411 of ARSE cDNA);
5′-CTC CTA TTT TGT GCG TGC TCT GAT TG) (nt
686–711 of ARSE cDNA); and selection primer 5′-CAT
CGA TAC GCG TCT GTG GAA TG (nt 2598–2621 of
pcDL; Takebe et al. 1988). The mutation corresponding
to C492Y was introduced into ARSE wild-type cDNA
by two successive rounds of PCR using the following
oligonucleotides: Tyr, 5′-GCC GGT GCC TAC TAT
GGA AGA AAGG (nt 1531–1555 of ARSE cDNA), and
TyrRev, 5′-CTT CCA TAG TAG GCA CCG GC (nt
1550–1531 of ARSE cDNA); MID3, 5′-CAG CTT TTC
ACT GCA GAC ATT TAT TG (nt 2067–2092 of the
cDNA); MID4, 5′-GCA TTA TTG TGA GAG GTT TCT
GCA CG (nt 1664–1690 of the cDNA); and ASE16, 5′-
GAC GTG TTC CCC ACC GTG GTC (nt 1540–1560
of the cDNA). In the preceding lists, the nucleotide sub-
stitutions are underlined. The DNA sequence of each
mutant construct was confirmed by sequence analysis;
for C492Y, the entire PCR product was sequenced. The
ARSD expression vector was constructed by cloning of
the full-length ARSD cDNA (Franco et al. 1995) into
the pcDL vector (Takebe et al. 1988).
Cos7 Cell Transfection and Protein Extract
Cos7 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FCS, 100 g
penicillin/ml, and 100 g streptomycin/ml, at 37C in 5%
CO2 atmosphere, and 10 mg wild-type (ARSE or ARSD)
and mutant (ARSE) cDNA expression vector constructs
were introduced into Cos7 cells, by electroporation us-
ing a BioRad Gene Pulser apparatus, and were seeded
in 25-cm2 flasks. The cells were harvested 24–72 h after
transfection and were resuspended in extraction buffer
(150 mM NaCl; 100 mM Tris-HCl, pH 7.5; and 1%
Triton X-100), and cell lysates were clarified by cen-
trifugation at 13,000 rpm to remove cell debris. To iso-
late glycoproteins, cell extracts were diluted 1:10 in con-
canavalin A buffer (0.1 M acetate buffer, pH 6; 1 M
NaCl; 1 mM CaCl2; 1 mM MgCl2; and 1 mM MnCl2)
and were incubated overnight with concanavalin A-Se-
pharose 4B (Sigma), at 4C. Concanavalin A-Sepharose
pellets were resuspended in SDS-PAGE sample buffer,
boiled, and loaded on the gel. To determine the asso-
ciation of ARSE with membranes, cells either were lysed
by sonication, in the presence of 0.5 M Na2CO3 (Fujiki
et al. 1982), or were extracted with Triton X-114 (150
mM NaCl; 100 mM Tris-HCl, pH 7.5; and 1% Triton
X-114), and the aqueous and detergent phases were sep-
arated as described elsewhere (Bordier 1981). As a con-
trol for transfection efficiency, 1 mg of a construct car-
rying a luciferase reporter gene under the control of a
strong promoter cytomegalovirus was cotransfected, and
luciferase activity was tested as described elsewhere
(Nordeen 1988).
Arylsulfatase Activity
Arylsulfatase activity, with the fluorogenic substrate
4MU sulfate, was assayed as described elsewhere
(Franco et al. 1995).
Production of Polyclonal Antibodies
The regions of amino acids 276–558 of ARSE and
amino acids 390–593 of ARSD were fused to the six-
histidine tag bacterial expression vector pQE (Qiagen)
and were produced in Escherichia coli, after induction
with isopropyl-b-D-thiogalactoside (IPTG). The His-
tagged proteins were purified on an NiNTA agarose col-
umn (Qiagen) and were used to immunize rabbits. ARSE
and ARSD antisera were precipitated with ammonium
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sulfate, and the antibodies were purified on a protein A-
Sepharose column.
Immunoblot
Ten micrograms of soluble cellular proteins was boiled
for 5 min in sample buffer, electrophoresed through 10%
SDS-PAGE, and electroblotted onto nitrocellulose mem-
branes (BioRad). The membranes were treated with 5%
dry milk in Tris-buffer saline with the addition of Tween
20 (TTBS [20 mM Tris-HCl, pH7; 50 mM NaCl; and
0.1% Tween 20]), to inhibit nonspecific binding. Anti-
ARSE antibody was used at a 1:200 dilution in TTBS.
Visualization of antibody binding was performed with
a secondary goat anti-rabbit IgG antibody conjugated
with alkaline phosphatase.
Immunofluorescence
Indirect immunofluorescence was performed on par-
aformaldehyde (PFA)-fixed transfected Cos7 cells. Cells
were permeabilized with 0.2% Triton X-100, blocked
with porcine serum, and incubated with anti-ARSE or
anti-ARSD antibody (1:400). Staining was obtained af-
ter incubation with secondary fluorescein isothiocyanate
(FITC)– or tetramethylrhodamine isothiocyanate
(TRITC)-conjugated isotype-specific antibodies. Specific
Golgi staining was obtained either by incubation of PFA-
fixed cells with 15 mg rhodamine-conjugated wheat germ
agglutinin (WGA)/ml (Sigma) or by double staining with
two commercially available anti-Golgi monoclonal an-
tibodies that recognize the b-COP (clone maD; Sigma)
and the Golgi 58K (clone 58K-9; Sigma) proteins.
Biosynthetic Labeling and SDS Analysis
Seventy-two hours after transfection, Cos7 cells were
starved for 2 h with methionine-free DMEM (Sigma).
The cells were labeled for 5–30 min with 150 mCi 35S-
methionine, in methionine-free DMEM containing 2%
dialyzed fetal bovine serum (FBS), and were chased for
1, 4, 8, and 20 h in DMEM medium supplemented with
10% FBS. The cells were harvested by scraping and were
lysed in 100 ml 0.05 M Tris-HCl buffer, pH 7.5, con-
taining 0.5% Triton X-100, 150 mM NaCl, 1 mM phen-
ylmethylsulfonyl flouride (PMSF), and 1 mM EDTA.
Cell lysates were clarified by centrifugation at 13,000
rpm, were diluted to 600 ml with 0.05 M Tris-HCl buffer
containing 150 mM NaCl, 1 mM PMSF, and 1 mM
EDTA, and were incubated for 2 h with 4 ml rabbit
preimmune serum and 35 ml protein A-Sepharose sus-
pension (1:1 in H2O). After centrifugation at 1,500 rpm,
ARSE was immunoprecipitated with 4 ml rabbit anti-
ARSE antiserum for 4 h. Immune complexes were pre-
cipitated with 35 ml protein A-Sepharose suspension,
were washed six times with 0.05 M Tris-HCl buffer, pH
7.5, containing 150 mM NaCl, 1 mM PMSF, and 1 mM
EDTA, and were analyzed by SDS-PAGE, followed by
fluorography.
Endoglycosidase H Treatment
Transfected Cos7 cells were pulse labeled for 30 min,
chased for 4 h, and treated as described above. Immune
complexes were solubilized in 1.25 M Tris-HCl buffer,
pH 6.8, containing 1% SDS, at 100C for 10 min. Su-
pernatants were diluted in 500 ml 0.1 M sodium acetate
buffer, pH 6.0, containing 1% 2-mercaptoethanol and
were incubated with 40 mU endoglycosidase H (Boh-
eringer) for 6 h. ARSE polypeptides were precipitated
with 10% tricholoroacetic acid (TCA) and were ana-
lyzed by SDS-PAGE.
Results
Characterization of ARSE in Transfected Cos7 Cells
We raised polyclonal antibodies against the predicted
C-terminal portion of the ARSE and ARSD proteins. The
regions of amino acids 276–558 of ARSE and amino
acids 390–593 of ARSD were fused to a six-histidine
tag bacterial expression vector and then were produced
in E. coli and used to immunize rabbits. Although the
antisera were raised against a region where these two
sulfatases share the lowest degree of homology (70%
identity) (Franco et al. 1995), both polyclonal antibodies
crossreacted with all members of the subfamily of
Xp22.3 sulfatases (ARSD, ARSE, ARSF, and STS), after
transfection in Cos7 cells (data not shown), hampering
the biochemical characterization of the endogenous
ARSE product in cellular extracts. Therefore, we limited
our study to the ARSE protein transiently expressed in
Cos7 cells.
After 30 min of metabolic labeling of Cos7 cells trans-
fected with the wild-type ARSE expression vector
(Franco et al. 1995), two polypeptides, of 68 and 60
kD, were immunoprecipitated by the rabbit anti-ARSE
antiserum. Both polypeptides are related to ARSE, since
they were not detected in mock cells (fig. 1a). Short
labeling times (5 min), followed by chases of 1–20 h,
showed that the 60-kD polypeptide is the precursor of
the enzyme. The 60-kD form was rapidly converted into
the mature 68-kD polypeptide (fig. 1b), which corre-
sponds to the form observed in western blot experi-
ments. The deduced amino acid sequence of ARSE pre-
dicts a protein of 589 residues, with a putative signal
peptide. The putative signal peptide consists of an N-
terminal region containing positively charged residues,
followed by a stretch of hydrophobic residues and a
more polar C-terminal region. Ala20–Val21 and
Ser23–Leu24 represent possible signal peptidase cleav-
age sites, since they both fulfill the (3, 1) rule (von
Heijne 1986). The molecular mass of the deduced pol-
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Figure 1 a, Immunoprecipitation and SDS-PAGE analysis of COS cells transfected with pcDL-ARSE. Mock (left) and transfected (right)
Cos7 cells were labeled with 35S-methionine for 30 min; ARSE-related polypeptides were immunoprecipitated, and the immunocomplexes were
analyzed by SDS-PAGE. Two bands, of 60 and 68 kD, were detectable in the Cos7 cells transfected with the ARSE cDNA. b, Biosynthesis and
stability of the ARSE gene product. Cos7 cells transfected with pcDL-ARSE were labeled for 5 min and were chased for variable periods. Cell
extracts were immunoprecipitated, and the immunocomplexes were analyzed by SDS-PAGE. After 5 min of labeling, only the 60-kD polypeptide
was detectable. This polypeptide was rapidly converted into the 68-kD form, which is the only molecular form visible after 1, 4, and 8 h of
chase; after 20 h, the 68-kD polypeptide was barely detectable. c, Glycosylation of the ARSE gene product. Cos7 cells transfected with pcDL-
ARSE were labeled for 30 min and were chased for 4 h. Cell extracts were immunoprecipitated; the immunocomplexes were denatured and
subjected to endoglycosidase treatment and were analyzed by SDS-PAGE, together with the untreated immunocomplexes. After endoglycosidase
H treatment, the 68-kD polypeptide was converted into the 60-kD form.
ypeptide chain, excluding the putative N-terminal signal
peptide, was calculated to be ∼61 kD, corresponding to
the apparent SDS-PAGE molecular weight of the pre-
cursor form.
After purification of transfected Cos7 cell extract on
concanavalin A-Sepharose, the band corresponding to
ARSE was retained among the glycosylated proteins (fig.
4A). Moreover, treatment with endoglycosidase H re-
duced the size of the 68-kD polypeptide by 8 kD, sug-
gesting that the increase in molecular size observed in
the maturation of ARSE is due to N-glycosylation (fig.
1c).
Intracellular Localization of ARSE
All the sulfatases identified thus far are lysosomal pro-
teins (Stein et al. 1989a; Hopwood and Morris 1990;
Neufeld and Muenzer 1995), with the exception of STS,
which has been localized in almost all membrane com-
partments—the rough and smooth endoplasmic reticu-
lum, the Golgi cisternae, the endosomes, the dense ly-
sosomes, and the plasma membrane (Willemsen et al.
1988; Stein et al. 1989b). We used indirect immunofluo-
rescence techniques to establish the subcellular locali-
zation of ARSE in transfected Cos7 cells. The anti-ARSE
antibody revealed a typical Golgi-apparatus staining 12,
24, 48, and 72 h after transfection. The Golgi locali-
zation was confirmed by double staining with rhoda-
mine-conjugated WGA, a lectin that binds with high-
affinity residues of N-acetyl-D-lucosamine present in
high concentration in the Golgi apparatus (Tartakoff
and Vassalli 1983). As shown in figure 2a and b, the
distribution of ARSE corresponds to that of WGA. The
ARSE localization also was confirmed by double staining
with antibodies raised against Golgi epitopes. By use of
monoclonal antibodies against b-COP (clone maD) (Pep-
perkok et al. 1993), the immunofluorescence staining
was confined mainly to the central perinuclear area in
the cell, which corresponds to the results observed with
anti-ARSE antiserum (fig. 2c and d), and was not su-
perimposable with a typical ER staining revealed by par-
allel transfection with the ARSD cDNA (fig. 2e and f)
and with STS (data not shown). A similar result was
obtained by use of a monoclonal antibody against the
Golgi 58K protein (clone 58K-9) (Bloom and Brashear
1989) as a marker of the Golgi apparatus (data not
shown). To verify that what we found corresponds to
the normal ARSE localization and not to an artifact that
is due to overexpression in the Cos7 cell system, we
Figure 2 Localization of ARSE in transfected cells. Cos7 cells were transfected with ARSE (a–d) and ARSD (e and f). NIH3T3 and RPE
cells were transfected with ARSE (g and h). a and b, Double staining using anti-ARSE antiserum, followed by FITC anti-rabbit antibody, and
rhodamine-conjugating WGA, respectively (#950). c and d,Double staining using anti-ARSE antiserum, followed by TRITC anti-rabbitantibody,
and monoclonal anti-Golgi 58K protein, followed by FITC anti-mouse antibody, respectively (#380). e and f, Double staining using anti-ARSD
antiserum, followed by TRITC anti-rabbit antibody, and monoclonal anti-Golgi 58K protein, followed by FITC anti-mouse antibody, respectively
(#380). g and h, Single staining using anti-ARSE antiserum, followed by TRITC anti-rabbit antibody (#950).
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Figure 3 Immunoblot of ARSE-transfected Cos7 cells solubilized
with either Na2CO3 (lanes 1 and 2) or Triton X-114 (lanes 3 and 4).
Lane 1, Supernatant after extraction with Na2CO3. Lane 2, Pellet. After
extraction with Triton X-114, the extract was separated into the aque-
ous (lane 3) and detergent (lane 4) phases.
Table 1
Arylsulfatase Activity of ARSE Mutants Transiently Transfected in Cos7 Cells
CELL
TYPE
ARYLSULFATASE ACTIVITY
(nmol 4MU/mg/h)
AVERAGE
NORMALIZED
ARYLSULFATASE
ACTIVITYb
(nmol 4MU/
mg/h)
Experiment 1 Experiment 2 Experiment 3
Raw
Data
Luciferase
Units Normalizeda
Raw
Data
Luciferase
Units Normalizeda
Raw
Data
Luciferase
Units Normalizeda
Wild type 28.5 13,801 28.5 20 58,151 20 10.98 13,3728 10.98 15.3  3.9
R12S 40 18,870 29.25 24 72,617 19.21 14.38 14,9721 12.84 20.40  4.7
R111P .16 8,492 .26 .31 94,878 .19 .35 187,219 .25 .26  .05
G137V 1.5 31,091 .66 .7 107,003 .38 .43 113,862 .5 .51  .08
G245R .41 16,640 .34 .27 98,129 .16 .71 186,170 .51 .33  .1
C492Y .85 13,010 .9 .09 76,892 .068 .11 173,666 .08 .34  .27
Cos7 .32 .14 .23 .23  .09
NOTE.—To control transfection efficiency and variability, all results were normalized by testing luciferase activity after cotransfection with
a luciferase reporter gene vector.
a By comparison of the luciferase activity of the mutants with the luciferase activity of the wild-type construct, to correct for transfection
variability.
b Average of the normalized activity results of at least four independent experiments.
tested several cell lines expressing a lower level of trans-
fected ARSE protein. Figure 2g and h shows localization
of this protein to the Golgi apparatus, in two of these
cell lines, NIH3T3 and RPEmsma (Schiaffino et al.
1996).
ARSE could not be solubilized by 0.5 M Na2CO3,
whereas, after Triton X-114 extraction, ARSE protein
was recovered in the detergent phase (fig. 3). This result
suggests that ARSE behaves as an integral membrane
protein. Similar to STS, ARSE contains two putative
membrane-spanning domains (amino acids 199–216
and amino acids 224–244) that are not present in ARSA
and ARSB, as was deduced from the hydrophobicity
profile (Peters et al. 1990; Franco et al. 1995). These
domains could be responsible for the anchoring of ARSE
to the Golgi cisternae membranes.
Arylsulfatase Activity of ARSE Mutants
Single nucleotide changes that produce the amino acid
substitutions R12S, R111P, G137V, G245R, and C492Y
were identified in patients affected with CDPX (Franco
et al. 1995; Parenti et al., 1997). To investigate the effect
of these missense mutations, the nucleotide changes lead-
ing to these amino acid substitutions were introduced
into the wild-type ARSE expression vector by site-di-
rected mutagenesis. Wild-type and mutant expression
plasmids were transiently transfected into Cos7 cells by
electroporation. After 48–72 h, the total cell extracts
and the culture medium were assayed for their ability
to hydrolyze the sulfate group from 4MU sulfate. No
residual arylsulfatase activity was detectable in the cul-
ture medium of the cells transfected with the wild-type
and mutant constructs. The extracts from cells trans-
fected with R111P, G137V, G245R, and C492Y mutant
constructs exhibited significantly lower arylsulfatase ac-
tivity, with loss of the catalytic properties of the ARSE
enzyme. The R12S construct exhibited activity compa-
rable to that of the normal enzyme (table 1). We studied
the effect of this latter mutation in relation to the pH
optimum and thermostability of the enzyme and on the
activity in the presence of Warfarin as an inhibitor
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(Franco et al. 1995). The R12S mutation behaved like
the wild-type enzyme, with respect to all these param-
eters (data not shown).
Detection of Mutated ARSE Protein Product
The presence of mutated ARSE polypeptide in trans-
fected Cos7 cell extracts was determined by immunoblot
analysis using anti-ARSE antibody. Although no enzyme
activity was expressed from the transfected cDNA, the
amount of ARSE crossreacting material visualized by
western blot was comparable to that found in the cells
expressing the wild-type cDNA. As expected, the
amount of crossreacting material of R12S also was com-
parable to that found using the wild-type cDNA (fig.
4A). To test for decreased stability of the mutant pro-
teins, Cos7 cells transfected with the ARSE cDNA car-
rying different point mutations were labeled for 30 min
and were chased for 1 , 4, 8, and 20 h. All ARSE mutants
showed apparently normal processing and stability. The
biosynthesis of the ARSE gene product carrying the sub-
stitution G137V is shown in figure 4B. Therefore, four
of these mutations cause a severe reduction in the activity
of the enzyme without altering the production and sta-
bility of the protein.
Since all ARSE mutants produced stable proteins, we
investigated the possibility that these amino acid sub-
stitutions could lead to a mislocalization of the enzyme.
Particularly, the R12S mutation residing in the putative
signal peptide and exhibiting normal arylsulfatase ac-
tivity was a candidate for this kind of alteration. Indirect
immunofluorescence data did not show any difference
in the distribution of this mutant protein (fig. 4C) or of
the other mutants (data not shown), with respect to the
wild-type protein. All these amino acid substitutions,
with the exception of R12S, lead to protein alterations
affecting the catalytic properties of ARSE, which proves
their involvement in the pathogenesis of CDPX.
Discussion
Although mutations in the ARSE gene cause CDPX,
the pathogenesis of the disease and the physiological role
of ARSE are still unknown. A number of observations
suggest that sulfate metabolism is essential for the cor-
rect composition of the bone and cartilage matrix (Ha¨st-
backa et al. 1994; Superti-Furga 1994). To try to better
understand the physiological role of this new arylsul-
fatase, we started a biochemical characterization of the
wild-type ARSE and of the mutants found in CDPX
patients.
We detected two molecular forms of ARSE, a 60-kD
and a 68-kD protein, in cell extracts after transfection.
The 60-kD polypeptide is quickly converted into a stable
68-kD form, which is likely to represent the mature en-
zyme, with an increase in size due to N-glycosylation.
The amino acid sequence contains four potential N-gly-
cosylation sites (asparagine residues 58, 125, 258, and
344). Assuming that the average mass of an oligosac-
charide is 2 kD, all four N-glycosylation sites possibly
are utilized, accounting for the 8-kD shift observed in
SDS-PAGE. The STS predicted sequence shows four po-
tential N-glycosylation sites, of which two are utilized
(Stein et al. 1989b). Interestingly, alignment of all human
sulfatases (Franco et al. 1995) indicates that three of
four STS potential N-glycosylation sites (Asn 47, 259,
and 333) are present in the ARSE sequence (Asn 58,
258, and 344), in the corresponding positions.
Localization of ARSE exclusively in the Golgi appa-
ratus is a unique feature among the sulfatases. Most
human sulfatase enzymes that have been identified are
localized in the lysosomes (Stein et al. 1989a; Hopwood
and Morris 1990; Neufeld and Muenzer 1995). The only
exception is STS, which is distributed in all the cellular
membrane compartments (rough and smooth endo-
plasmic reticulum, the Golgi apparatus, and lysosomes)
and on the plasma membrane (Willemsen et al. 1988;
Stein et al. 1989b). ARSE is likely to be anchored to the
Golgi cisternae, through the two predicted transmem-
brane domains, since it is not solubilized by Na2CO3 or
0.5 M KCl (data not shown) and since it behaves as an
integral membrane protein, after extraction with Triton
X-114. The distribution of the enzyme in a neutral pH
compartment is consistent with the pH optimum ob-
served for ARSE arylsulfatase activity (Franco et al.
1995). More detailed experiments are required to define
the exact distribution of ARSE within the Golgi sub-
compartments and to determine its topology in the
membrane, although these preliminary data on its lo-
calization may help in the identification of the natural
substrate.
These biochemical findings, together with previous
data, indicate that the sulfatase gene cluster in Xp22.3
(ARSD, ARSE, ARSF, and STS) represents a subfamily
of arylsulfatases of relatively recent origin. In addition
to sharing the highest degree of sequence homology
(Franco et al. 1995) and the same genomic organization
(Meroni et al. 1996), these sulfatases show a putative
transmembrane domain that is absent in ARSA and
ARSB. Immunofluorescence results indicate that ARSD
and ARSF (G. Meroni, unpublished data) are ER pro-
teins, confirming the nonlysosomal nature of the Xp22.3
sulfatases.
Evidence that ARSE is implicated in CDPX was de-
rived from indirect observations. Screening by SSCP and
sequence analysis of DNA from 27 unrelated patients
with phenotypes comparable to that of CDPX revealed
point mutations in six of these patients, in the coding
region of the ARSE gene; these mutations were not found
in 120 control chromosomes (Franco et al. 1995; Parenti
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Figure 4 A, Immunoblot analysis of ARSE mutants. Total extracts of cells transfected with the ARSE wild-type and mutant cDNAs were
subjected to SDS-PAGE, followed by immunoblotting with anti-ARSE antiserum. B, Biosynthesis and stability of the wild-type and G137V
mutant ARSE. Cos7 cells transfected with the constructs carrying either the wild-type or the mutated ARSE cDNA were labeled for 30 min
and were chased for variable periods. Cell extracts were immunoprecipitated, and the immunocomplexes were subjected to SDS-PAGE analysis;
the results obtained with the construct carrying the mutant ARSE cDNA are shown (right) as compared with the results obtained with the
wild-type cDNA (left). C, R12S ARSE-transfected Cos7 cells stained with anti-ARSE antiserum, followed by TRITC anti-rabbit antibody.
et al., 1997). Other nucleotide substitutions leading to
missense mutations have been found in the ARSE coding
region (L. Sheffield, personal communication). In con-
trast, no mutations were found in the ARSD and ARSF
genes. Genetic heterogeneity in patients with phenotypes
comparable to that of CDPX has been suggested (Franco
et al. 1995), to explain ARSE mutations that have been
found only in a minority of the screened patients. How-
ever, formal proof that the mutations in the ARSE se-
quence interfere with the activity of the ARSE gene prod-
uct was not available. The mutations were scattered over
the entire sequence of the cDNA, involving variably con-
served amino acid residues of the ARSE protein. Two
of the mutations resulted in nonconservative amino acid
substitutions.
Many amino acid substitutions in the known sulfa-
tases have proved to be responsible for the deficiency of
activity observed in the respective disorders. In recent
years, much attention has been paid to the mechanisms
involved in the hydrolysis of sulfate ester bonds by sul-
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fatases. A major breakthrough in the understanding of
the function of sulfatases has emerged recently from the
observation that sulfatases undergo a common and
unique co- or posttranslational modification, probably
occurring in the endoplasmic reticulum, in which a cys-
teine residue is converted into a 2-amino-3-oxopropionic
acid or a serine semialdehyde. Moreover, this finding has
been fundamental to uncovering the basis of the MSD
disorder (Schmidt et al. 1995; Selmer et al. 1996). Re-
cently, the study of the crystal structure of ARSB (Bond
et al. 1997) has added additional insight into the mech-
anisms of sulfate hydrolysis by sulfatases. The active site
of the enzyme has been characterized and has been
shown to display unique features. Modified cysteine res-
idue 91 and a metal ion are located at the base of a
substrate-binding pocket. Some amino acid residues con-
served throughout the sulfatase family play a role in
stabilizing the calcium ion and the sulfate ester in the
active site.
To confirm the correlation between the mutations and
the occurrence of CDPX, we reproduced in vitro, by site-
directed mutagenesis, five of the mutations described
previously. The ARSE full-length cDNAs carrying the
mutations were expressed in Cos cells, and the effects
of the mutations on activity, biosynthesis, and subcel-
lular localization of the enzyme were studied. Since the
mutated constructs yielded a relatively normal level of
ARSE polypeptide with regular molecular size, stability,
and subcellular distribution, they probably do not in-
duce dramatic structural changes in the protein.
Four of the mutated constructs, however, directed the
synthesis of polypeptides with severely reduced activity,
indicating that the mutated amino acids are critical for
the catalytic activity of the ARSE enzyme. The nucleotide
alteration leading to the R12S substitution did not ap-
peared to alter the enzyme activity, compared with the
wild-type ARSE construct. Immunofluorescence studies
have shown that COS cells transfected with R12S cDNA
contain a normal level of the ARSE polypeptides in the
Golgi compartment, ruling out the hypothesis that this
mutation, which is located in the putative leader se-
quence, could affect the targeting of the ARSE protein
to the correct subcellular compartment. A possible ex-
planation is that the R12S is in fact a rare neutral mu-
tation. In principle, the hypothesis that the R12S ARSE
enzyme retains activity toward the artificial substrate
4MU sulfate but is catalytically inactive against its nat-
ural substrate cannot be excluded. The mutation that
changes a glycine residue at position 137 to a valine was
considered to be of particular interest. In fact, glycine
137 is located in a highly conserved region and is found
at the same position in all known human sulfatases.
Furthermore, a mutation involving the glycine residue
at the same position in the ARSB gene already has been
detected in a patient with mucopolysaccharidosis VI
(Maroteaux-Lamy syndrome; Wicker et al. 1991). The
authors demonstrated that this mutation severely im-
paired the processing and stability of the ARSB protein,
whereas the catalytic activity of the enzyme was not
affected. Our findings showed that the G137V ARSE
protein is synthesized normally but that the catalytic
activity, tested by use of the artificial substrate 4MU
sulfate, is reduced markedly. Therefore, although this
residue is conserved between the two arylsulfatases, the
same alteration probably leads to different consequences
for the enzyme’s properties, likely owing to the different
processing and topology of the two sulfatases in the cell.
The mutations R111P and G245R, in exons 4 and 5,
respectively, resulted in two nonconservative amino acid
substitutions, changing a basic amino acid to a nonpolar
amino acid and vice versa. It should be noted that the
substitution of an arginine 111 with a proline residue
could interrupt the correct secondary structure of the
ARSE enzyme, introducing an abnormal turn in a con-
served region of the protein. Mutation C492Y, in exon
10, involves a residue that is conserved only among the
Xp22.3 sulfatases. This substitution may interfere with
the formation of a disulfide bond.
Alignment of the ARSE amino acid sequence with
those of all the other known sulfatases revealed that all
but one of the residues (His in position 354 of ARSE,
which is Ash in position 301 of ARSB) involved in metal
ion coordination and stabilization of the sulfate ester are
conserved, on the basis of the crystal structure of ARSB
(Bond et al. 1997). The mutations found in CDPX pa-
tients are scattered along the entire length of the protein,
but none of these mutations involve the amino acids that
form the catalytic pocket. These mutations do not affect
the active site of the enzyme and still allow the produc-
tion of an apparently correct protein, in terms of stability
and processing. Therefore, until new data are available,
we can theorize only that these substitutions are essential
for the fine folding required for the production of a
catalytically active enzyme.
In conclusion, we have confirmed that four of the
mutations identified in CDPX patients are very likely to
be the cause of the disease. Although the sulfatases share
regions of high sequence similarity along their entire
lengths, little is known about the structure-function re-
lationship of these sequences. The newly defined crystal
structure, together with single- or multiresidue muta-
genesis, will help to define the sequence-function rela-
tionship in this family of enzymes.
Acknowledgments
We are grateful to Rosaria Tuzzi for technical work. We
thank Elena I. Rugarli and Brunella Franco for critically read-
ing the manuscript and Melissa Smith for help in preparing
the manuscript. The support of the Italian Te´le´thon Founda-
Daniele et al.: ARSE Mutations in Chondrodysplasia Punctata 571
tion is gratefully acknowledged. This work also was supported
by Te´le´thon grant E.283 (to G.P.).
References
Ballabio A, Parenti G, Carrozzo R, Sebastio G, Andria G,
Buckle V, Fraser N, et al (1987) Isolation and characteri-
zation of a steroid sulphatase cDNA clone: genomic dele-
tions in patients with X-chromosome-linked ichthyosis. Proc
Natl Acad Sci USA 84:4519–4523
Ballabio A, Shapiro LJ (1995) STS deficiency and X-linked
ichthyosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds)
The metabolic and molecular bases of inherited disease. Mc-
Graw-Hill, New York, pp 2999–3022
Bloom GS, Brashear TA (1989) A novel 58-kDa protein as-
sociates with the Golgi apparatus and microtubules. J Biol
Chem 264:16083–16092
Bond CS, Clements PR, Ashby SJ, Collyer CA, Harrop SJ,
Hopwood JJ, Guss JM (1997) Structure of a human lyso-
somal sulfatase. Structure 5:277–289
Bordier C (1981) Phase separation of integral membrane pro-
teins in Triton X-114 solution. J Biol Chem 256:1604–1607
Curry CJR, Magenis E, Brown M, Lanman JT Jr, Tsai J,
O’Lague P, Goodfellow P, et al (1984) Inherited chondro-
dysplasia punctata due to a deletion of the terminal short
arm of an X chromosome. N Engl J Med 311:1010–1014
Franco B, Meroni G, Parenti G, Levilliers J, Bernard L, Gebbia
M, Cox L, et al (1995) A cluster of sulfatase genes on
Xp22.3: mutations in chondrodysplasia punctata (CDPX)
and implications for Warfarin embryopathy. Cell 81:15–25
Fujiki Y, Hubbard AL, Fowler S, Lazaro PB (1982) Isolation
of intracellular membranes by means of sodium carbonate
treatment: application to endoplasmic reticulum. J Cell Biol
93:97–102
Hall JG, Pauli RM, Wilson KM (1980) Maternal and fetal
sequelae of anticoagulation during pregnancy. Am J Med
68:122–140
Ha¨stbacka J, de la Chapelle A, Mahtani MM, Clines G, Reeve-
Daly MP, Daly M, Hamilton BA, et al (1994) The dia-
strophic dysplasia gene encodes a novel sulfate transporter:
positional cloning by fine-structure linkage disequilibrium
mapping. Cell 78:1073–1087
Hopwood JJ, Morris CP (1990) The mucopolysaccharidoses:
diagnosis, molecular genetics and treatment. Mol Biol Med
7:381–404
Kolodny EH, Fluharty AL (1995) Metachromatic leukodys-
trophy and multiple sulfatase deficiency: sulfatide lipidosis.
In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The met-
abolic and molecular bases of inherited disease. McGraw-
Hill, New York, pp 2693–2741
Meroni G, Franco B, Archidiacono N, Messali S, Andolfi G,
Rocchi M, Ballabio A (1996) Characterization of a cluster
of sulfatase genes on Xp22.3 suggests gene duplications in
an ancestral pseudoautosomal region. Hum Mol Genet 5:
423–431
Neufeld EF, Muenzer J (1995) The mucopolysaccharidoses. In:
Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic
and molecular bases of inherited disease. McGraw-Hill,
New York, pp 2465–2494
Nordeen SK (1988) Luciferase reporter gene vectors for anal-
ysis of promoters and enhancers. Biotechniques 6:454–457
Parenti G, Buttitta P, Meroni G, Franco B, Bernard L, Rizzolo
MG, Brunetti-Pierri N, et al. (1997) X-linked recessive
chondrodysplasia punctata due to a new point mutation of
the ARSE gene. Am J Med Genet 73:139–143
Parenti G, Meroni G, Ballabio A (1997) The sulfatase gene
family. Curr Opin Genet Dev 7:386–391
Pauli RM, Lian JB, Mosher DF, Suttie JW (1987) Association
of congenital deficiency of multiple vitamin K–dependent
coagulation factors and the phenotype of the Warfarin em-
bryopathy: clues to the mechanism of teratogenicity of cou-
marin derivatives. Am J Hum Genet 41:566–583
Pepperkok R, Scheel J, Horstmann H, Hauri HP, Griffiths G,
Kreis TE (1993) b-cop is essential for biosynthetic membrane
transport from the endoplasmic reticulum to the Golgi com-
plex in vivo. Cell 74:71–82
Peters C, Schmidt B, Rommerskirch W, Rupp K, Zu¨hlsdorf M,
Vingron M, Meyer HE, et al (1990) Phylogenetic conser-
vation of arylsulfatases cDNA cloning and expression of
human arylsulfatase. J Biol Chem 265:3374–3381
Puca A, Zollo M, Repetto M, Andolfi G, Guffanti A, Simon
G, Ballabio A, et al (1997) Identification by shotgun se-
quencing, genomic organization, and functional analysis of
a fourth arylsulphatase gene (ARSF) from the Xp22.3 re-
gion. Genomics 42:192–199
Schiaffino MV, Baschirotto C, Pellegrini G, Montalti S, Tac-
chetti C, De Luca M, Ballabio A (1996) The ocular albinism
type I (OA1) gene product is a membrane glycoprotein lo-
calized to melanosomes. Proc Natl Acad Sci USA 93:
9055–9060
Schmidt B, Selmer T, Ingendoh A, yon Figura K (1995) A novel
amino acid modification in sulfatases that is defective in
multiple sulfatase deficiency. Cell 82:271–278
Selmer T, Hallmann A, Schmidt B, Sumper M, Von Figura K
(1996) The evolutionary conservation of a novel protein
modification, the conversion of cysteine to serine semialde-
hyde in arylsulfatase from Volvox carteri. Eur J Biochem
238:341–345
Stein C, Gieselmann V, Kreysing J, Schmidt B, Pohlmann R,
Waheed A, Meyer HE, et al (1989a) Cloning and expression
of human arylsulfatase A. J Biol Chem 264:1252–1259
Stein C, Hille A, Seidel J, Rijnbout S, Waheed A, Schmidt B,
Geuze H, et al (1989b) Cloning and expression of human
steroid-sulfatase. J Biol Chem 264:13865–13872
Superti-Furga A (1994) A defect in the metabolic activation
of sulfate in a patient with achondrogenesis type IB. Am J
Hum Genet 55:1137–1145
Takebe Y, Seiki M, Fujisawa J-I, Hoy P, Yokota K, Arai K-I,
Yoshida M, et al (1988) SRa promoter: an efficient and
versatile mammalian cDNA expression system composed of
the simian virus 40 early promoter and the R-U5 segment
of human T-cell leukemia virus type 1 long terminal repeat.
Mol Cell Biol 8:466–472
Tartakoff AM, Vassalli P (1983) Lectin-binding sites as mark-
ers of Golgi subcompartments: proximal-to-distal matura-
tion of oligosaccharides. J Cell Biol 97:1243–1248
von Heijne G (1986) A new method for predicting signal se-
quence cleavage sites. Nucleic Acids Res 14:4683–4690
Wang I, Franco B, Ferrero GB, Chinault AC, Weissenbach J,
572 Am. J. Hum. Genet. 62:562–572, 1998
Chumakov I, Le Paslier D, et al (1995) High-density physical
mapping of a 3-Mb region in Xp22.3 and refined locali-
zation of the gene for X-linked recessive chondrodysplasia
punctata (CDPX1). Genomics 26:229–238
Wicker G, Prill V, Brooks D, Gibson G, Hopwood J, von
Figura K, Peters C (1991) Mucopolysaccharidosis VI (Mar-
oteaux-Lamy syndrome). J Biol Chem 266:21386–21391
Willemsen R, Kroos M, Hoogeveen AT, van Dongen JM, Par-
enti G, van der Loos CM, Reuser AJJ (1988) Ultrastructural
localization of steroid sulphatase in cultured human fibro-
blasts by immunocytochemistry: a comparative study with
lysosomal enzymes and the mannose 6-phosphate receptor.
Histochem J 20:41–51
Yen PH, Allen E, Marsh B, Mohandas T, Wang N, Taggart
RT, Shapiro LJ (1987) Cloning and expression of steroid
sulfatase cDNA and the frequent occurrence of deletions in
STS deficiency: implication for X-Y interchange. Cell 49:
443–454
